Supplemental Material

**Serum metabolic profiling in rheumatic heart disease and degenerative aortic stenosis**

**Running title:** Metabolomics in RHD and calcific aortic stenosis

Daniel W. Mutithu,a,b,c MSc; Jennifer A. Kirwan,d,e PhD; Henry A. Adeola,f PhD BDS; Olukayode O. Aremu,a,b,c MSc; Evelyn N. Lumngwena,c,g PhD; Mary Familusi,h MSc; Lubbe Wiesner,i PhD; Sebastian Skatulla,h PhD; Richard Naidoo,j PhD; Ntobeko A. B. Ntusi,a,b,c,k\* DPhil MD

aDivision of Cardiology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, and Groote Schuur Hospital, 7925 Cape Town, South Africa.

bCape Heart Institute, Faculty of Health Sciences, University of Cape Town, 7925 Cape Town, South Africa.

cExtramural Unit on Intersection of Noncommunicable Diseases and Infectious Diseases, South African Medical Research Council, 7501 Cape Town, South Africa.

dMetabolomics Platform, Berlin Institute of Health at Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.

eMax-Delbrück-Center Max-Delbrück-Center (MDC) for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.

fHair and Skin Research Laboratory, Division of Dermatology, Department of Medicine, University of Cape Town, 7925 Cape Town, South Africa.

gSchool of Clinical Medicine, University of Witwatersrand, 2193 Johannesburg, South Africa.

hComputational Continuum Mechanics Research Group, Department of Civil Engineering, Faculty of Engineering and the Built Environment, University of Cape Town, 7925 Cape Town, South Africa.

iDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, 7925 Cape Town, South Africa.

jDivision of Anatomical Pathology, Department of Pathology, University of Cape Town, and National Health Laboratory Services, 7925 Cape Town South Africa.

kCape Universities Body Imaging Centre, Faculty of Health Sciences, University of Cape Town, 7925 Cape Town, South Africa.

**Table S1**. Gradient conditions for reverse phase metabolites separation

|  |  |  |
| --- | --- | --- |
| Time (Min) | Flow (mL/Min) | % A |
| 2 | 0.4 | 98 |
| 45 | 0.4 | 5 |
| 47 | 0.4 | 5 |
| 47.1 | 0.4 | 98 |
| 60 | 0.4 | 98 |

**Table S2**. Summary of the pathway mapping by the metabolites detected and different in RHD and controls.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Total | Hits | Pathway coverage (%) | Raw p | FDR adj. p | Impact | Mapped metabolites |
| Glycerophospholipid metabolism | 36 | 2 | 13.89 | 0.00000572 | 0.000481 | 0.26961 | LysoPC(16:1), LysoPE(0:0/22:5) |
| Linoleic acid metabolism | 5 | 1 | 40 | 0.000641 | 0.026903 | 1 | Linoleic acid |
| Valine, leucine, and isoleucine biosynthesis | 8 | 2 | 25 | 0.001768 | 0.049509 | 0 | Isoleucine, Valine |
| Aminoacyl-tRNA biosynthesis | 48 | 3 | 6.25 | 0.006411 | 0.13464 | 0 | Valine, Isoleucine, Tryptophan |
| Arachidonic acid metabolism | 36 | 1 | 5.56 | 0.034843 | 0.58536 | 0 | 15S-HETE |
| Valine, leucine, and isoleucine degradation | 40 | 2 | 5 | 0.042331 | 0.59263 | 0 | Isoleucine, Valine |

**Table S3**. Summary of the pathway mapping by the metabolites detected and different in AS and controls.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Total | Hits | Pathway coverage (%) | Raw p | FDR adj. p | Impact | Mapped metabolites |
| Glycerophospholipid metabolism | 36 | 2 | 16.67 | 0.000000268 | 0.0000225 | 0.42215 | LysoPC(17:0/0:0), PA(8:0/13:0), |
| Phosphatidylinositol signalling system | 28 | 1 | 7.14 | 0.02505 | 0.7014 | 0.09899 | PA(8:0/13:0) |
| Arachidonic acid metabolism | 36 | 1 | 5.56 | 0.040064 | 0.71151 | 0 | 15S-HETE |

**Table S4**. Summary of the pathway mapping by the metabolites detected and different in RHD and AS.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Total | Hits | Pathway coverage (%) | Raw p | FDR adj. p | Impact | Mapped metabolites |
| Glycerophospholipid metabolism | 36 | 2 | 16.67 | 0.0000004.39 | 0.0000369 | 0.28311 | DG(a-15:0/i-12:0/0:0), LysoPE(0:0/22:5) |
| Glycine, serine, and threonine metabolism | 33 | 2 | 6.06 | 0.036404 | 0.92684 | 0.05034 | Betaine, Creatine |
| Valine, leucine, and isoleucine degradation | 40 | 2 | 5 | 0.055169 | 0.92684 | 0 | Acetoacetate, Valine |

**Table S5**. Summary of the metabolites’ Spearman’s or Point-Biserial correlations analyses with LVEF, LVMI, LVEDV, LVESV, LA area, and valves calcification after adjusting for sex, age, race, BMI, hypertension, diabetes, and batch effects in patients with rheumatic heart disease .

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Calcification rs | p-value | Calcification raw rs | p-value | LVMI (g/m2) rs | p-value | LVMI (g/m2) raw rs | p-value | LVEDV (ml) rs | p-value | LVEDV (ml) raw rs | p-value | LVESV (ml) rs | p-value | LVESV raw (ml) rs | p-value | LVEF (%) rs | p-value | LVEF (%) raw rs | p-value | LA Area (cm2) rs | p-value | LA area raw (cm2) rs | p-value |
| Cholestoric acid-Deoxycholate | -0.03 | 0.903 | 0.15 | 0.419 | -0.12 | 0.556 | -0.13 | 0.523 | -0.17 | 0.410 | -0.17 | 0.339 | 0.20 | 0.326 | 0.19 | 0.283 | -0.64 | 0.000 | -0.55 | 0.001 | 0.28 | 0.151 | 0.18 | 0.319 |
| Cholestoric acid/Deoxycholate | 0.01 | 0.964 | -0.21 | 0.230 | 0.07 | 0.724 | 0.08 | 0.707 | 0.13 | 0.522 | 0.12 | 0.499 | -0.35 | 0.077 | -0.26 | 0.150 | 0.57 | 0.002 | 0.53 | 0.001 | -0.34 | 0.084 | -0.24 | 0.186 |
| Propionylcarnitine/Acetoacetate | -0.19 | 0.360 | -0.10 | 0.565 | -0.57 | 0.003 | -0.57 | 0.003 | -0.47 | 0.014 | -0.18 | 0.317 | -0.13 | 0.534 | -0.18 | 0.324 | -0.26 | 0.193 | -0.12 | 0.500 | -0.02 | 0.933 | -0.09 | 0.609 |
| Butyrylcarnitine | -0.09 | 0.662 | 0.12 | 0.489 | 0.05 | 0.820 | 0.04 | 0.846 | -0.04 | 0.842 | 0.10 | 0.572 | 0.11 | 0.598 | 0.24 | 0.183 | -0.54 | 0.004 | -0.38 | 0.028 | 0.32 | 0.101 | 0.15 | 0.418 |
| 13-Docosenamide | 0.14 | 0.505 | 0.15 | 0.419 | -0.12 | 0.571 | -0.12 | 0.567 | -0.35 | 0.071 | -0.09 | 0.612 | 0.13 | 0.529 | 0.16 | 0.375 | -0.50 | 0.008 | -0.41 | 0.018 | 0.36 | 0.063 | 0.31 | 0.084 |
| (acetoacetate+deoxycholate+cholestonic)/(Carnitines) | -0.14 | 0.488 | -0.19 | 0.297 | 0.08 | 0.709 | 0.08 | 0.687 | 0.28 | 0.165 | 0.16 | 0.373 | -0.13 | 0.511 | -0.15 | 0.420 | 0.46 | 0.016 | 0.43 | 0.012 | -0.35 | 0.078 | -0.30 | 0.094 |
| Inosine-Valine | 0.12 | 0.547 | 0.15 | 0.397 | -0.08 | 0.692 | -0.11 | 0.595 | -0.13 | 0.510 | 0.07 | 0.688 | 0.00 | 0.989 | 0.02 | 0.899 | -0.05 | 0.786 | 0.03 | 0.852 | 0.46 | 0.017 | 0.37 | 0.032 |
| 7-Hoca | -0.09 | 0.670 | 0.10 | 0.591 | -0.26 | 0.206 | -0.27 | 0.190 | -0.28 | 0.152 | -0.19 | 0.293 | 0.13 | 0.505 | 0.11 | 0.550 | -0.45 | 0.017 | -0.35 | 0.043 | 0.19 | 0.352 | 0.09 | 0.638 |
| LysoPC(22:6/0:0) | -0.25 | 0.216 | 0.01 | 0.939 | 0.02 | 0.935 | 0.01 | 0.960 | -0.09 | 0.648 | 0.07 | 0.692 | 0.40 | 0.040 | 0.34 | 0.053 | -0.43 | 0.024 | -0.37 | 0.036 | 0.26 | 0.196 | 0.17 | 0.337 |
| Keto-hydroxypimelic acid | -0.05 | 0.827 | 0.06 | 0.730 | 0.42 | 0.032 | 0.42 | 0.036 | 0.40 | 0.037 | 0.26 | 0.150 | 0.41 | 0.031 | 0.37 | 0.034 | -0.03 | 0.880 | -0.11 | 0.532 | 0.07 | 0.725 | 0.01 | 0.948 |
| LA/3-Formylindole | 0.17 | 0.402 | 0.03 | 0.878 | 0.10 | 0.621 | 0.10 | 0.642 | -0.07 | 0.734 | -0.13 | 0.477 | -0.16 | 0.425 | -0.17 | 0.340 | 0.20 | 0.317 | 0.23 | 0.196 | 0.41 | 0.035 | 0.38 | 0.028 |
| Propionylcarnitine\*Acetoacetate | -0.07 | 0.725 | 0.09 | 0.618 | -0.41 | 0.036 | -0.41 | 0.040 | -0.39 | 0.042 | -0.18 | 0.329 | -0.14 | 0.501 | -0.18 | 0.326 | -0.13 | 0.507 | -0.07 | 0.685 | -0.11 | 0.588 | -0.17 | 0.356 |
| Deoxycholate\*Cholestoric acid | 0.09 | 0.667 | -0.19 | 0.297 | 0.20 | 0.334 | 0.20 | 0.331 | 0.25 | 0.202 | 0.16 | 0.384 | -0.12 | 0.536 | -0.06 | 0.749 | 0.40 | 0.040 | 0.36 | 0.041 | -0.19 | 0.333 | -0.09 | 0.636 |
| LysoPE(0:0/22:5) | -0.01 | 0.949 | 0.01 | 0.939 | 0.18 | 0.392 | 0.17 | 0.404 | 0.14 | 0.490 | 0.04 | 0.844 | 0.40 | 0.036 | 0.39 | 0.025 | -0.38 | 0.049 | -0.33 | 0.065 | 0.29 | 0.149 | 0.13 | 0.486 |

**Table S6**. Summary of the metabolites’ Spearman’s or Point-Biserial correlations analyses with LVEF, LVMI, LVEDV, LVESV, LA area, and valves calcification after adjusting for sex, age, race, BMI, hypertension, diabetes, and batch effects in patients with degenerative aortic stenosis.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Calcification rs | p-value | Calcification raw rs | p-value | LVMI (g/m2) rs | p-value | LVMI raw (g/m2) rs | p-value | LVEDV (ml) rs | p-value | LVEDV raw (ml) rs | p-value | LVESV (ml) rs | p-value | LVESV raw (ml) rs | p-value | LVEF (%) rs | p-value | LVEF raw (ml) rs | p-value | LA area (cm2) rs | p-value | LA area raw rs | p-value |
| 10-Nitroelaidic acid | 0.84 | 0.371 | 0.55 | 0.127 | 0.93 | 0.236 | -0.03 | 0.947 | 0.99 | 0.075 | -0.36 | 0.346 | 1.00 | 0.011 | -0.20 | 0.606 | 0.83 | 0.374 | 0.25 | 0.521 | 0.92 | 0.259 | 0.27 | 0.483 |
| 3-Formylindole | 1.00 | 0.049 | 0.55 | 0.127 | 0.96 | 0.184 | 0.35 | 0.359 | 0.86 | 0.345 | -0.02 | 0.965 | 0.78 | 0.431 | 0.09 | 0.824 | 0.32 | 0.793 | -0.33 | 0.385 | 0.48 | 0.678 | 0.64 | 0.061 |
| 3-Formylindole\*LA | -0.44 | 0.707 | -0.41 | 0.272 | -0.62 | 0.572 | -0.60 | 0.087 | -0.80 | 0.411 | -0.34 | 0.371 | -0.87 | 0.325 | -0.08 | 0.841 | -1.00 | 0.037 | -0.30 | 0.437 | -0.99 | 0.077 | -0.30 | 0.425 |
| 3-Formylindole-LA | 0.39 | 0.743 | 0.55 | 0.127 | 0.58 | 0.607 | 0.15 | 0.704 | 0.76 | 0.447 | -0.18 | 0.638 | 0.84 | 0.361 | -0.03 | 0.947 | 1.00 | 0.002 | 0.43 | 0.250 | 0.98 | 0.113 | 0.60 | 0.087 |
| Acetoacetate/Propionylcarnitine | -0.59 | 0.601 | -0.41 | 0.272 | -0.74 | 0.466 | -0.08 | 0.841 | -0.89 | 0.305 | 0.13 | 0.738 | -0.94 | 0.219 | -0.17 | 0.671 | -0.97 | 0.143 | 0.03 | 0.948 | -1.00 | 0.028 | -0.77 | 0.014 |
| acetylcarnitine/Acetoacetate | 0.88 | 0.309 | 0.55 | 0.127 | 0.96 | 0.173 | 0.26 | 0.497 | 1.00 | 0.013 | -0.19 | 0.622 | 0.99 | 0.074 | 0.09 | 0.824 | 0.77 | 0.436 | -0.07 | 0.880 | 0.88 | 0.321 | 0.56 | 0.119 |
| Butyrylcarnitine | 0.98 | 0.141 | 0.55 | 0.127 | 1.00 | 0.005 | 0.29 | 0.454 | 0.97 | 0.155 | -0.10 | 0.806 | 0.93 | 0.242 | 0.20 | 0.606 | 0.58 | 0.604 | 0.37 | 0.336 | 0.72 | 0.489 | 0.55 | 0.126 |
| Butyrylcarnitine\*Acetoacetate | 0.53 | 0.646 | 0.55 | 0.127 | 0.69 | 0.511 | 0.28 | 0.468 | 0.85 | 0.350 | -0.23 | 0.558 | 0.92 | 0.264 | -0.33 | 0.385 | 0.99 | 0.098 | 0.53 | 0.148 | 1.00 | 0.016 | -0.12 | 0.755 |
| Butyrylcarnitine\*Propionylcarnitine | -0.97 | 0.151 | -0.55 | 0.127 | -1.00 | 0.015 | -0.50 | 0.174 | -0.97 | 0.145 | -0.08 | 0.841 | -0.93 | 0.231 | -0.24 | 0.543 | -0.60 | 0.594 | -0.27 | 0.493 | -0.73 | 0.479 | -0.30 | 0.425 |
| Butyrylcarnitine/Acetoacetate | -0.36 | 0.767 | 0.41 | 0.272 | -0.55 | 0.632 | -0.26 | 0.497 | -0.74 | 0.471 | -0.59 | 0.093 | -0.82 | 0.385 | -0.70 | 0.037 | -1.00 | 0.023 | 0.08 | 0.843 | -0.98 | 0.138 | -0.45 | 0.221 |
| Butyrylcarnitine+Propionylcarnitine | 0.51 | 0.659 | 0.55 | 0.127 | 0.68 | 0.524 | 0.18 | 0.638 | 0.84 | 0.363 | -0.24 | 0.543 | 0.91 | 0.277 | 0.10 | 0.806 | 0.99 | 0.086 | 0.57 | 0.121 | 1.00 | 0.029 | 0.53 | 0.141 |
| Cholestoric acid/Deoxycholate | -0.93 | 0.241 | -0.27 | 0.476 | -0.99 | 0.106 | -0.24 | 0.543 | -1.00 | 0.055 | -0.08 | 0.841 | -0.98 | 0.141 | -0.41 | 0.274 | -0.70 | 0.504 | -0.03 | 0.948 | -0.82 | 0.389 | -0.71 | 0.034 |
| Cholestoric acid-Deoxycholate | -0.97 | 0.150 | 0.41 | 0.272 | -1.00 | 0.015 | 0.01 | 0.982 | -0.97 | 0.146 | -0.24 | 0.543 | -0.93 | 0.232 | -0.60 | 0.087 | -0.59 | 0.595 | 0.42 | 0.270 | -0.73 | 0.480 | -0.32 | 0.398 |
| Deoxycholate\*Cholestoric acid | -0.98 | 0.118 | -0.41 | 0.272 | -1.00 | 0.017 | -0.30 | 0.439 | -0.96 | 0.178 | 0.03 | 0.929 | -0.92 | 0.264 | -0.38 | 0.309 | -0.55 | 0.626 | -0.03 | 0.948 | -0.69 | 0.512 | -0.64 | 0.061 |
| Glucose+AA | -0.34 | 0.782 | 0.00 | 1.000 | -0.53 | 0.647 | -0.39 | 0.297 | -0.72 | 0.486 | -0.44 | 0.231 | -0.81 | 0.400 | -0.04 | 0.911 | -1.00 | 0.038 | 0.33 | 0.385 | -0.97 | 0.152 | -0.08 | 0.841 |
| Indolepropionic acid | -0.38 | 0.749 | -0.14 | 0.725 | -0.57 | 0.614 | -0.50 | 0.174 | -0.76 | 0.453 | -0.39 | 0.297 | -0.84 | 0.367 | -0.06 | 0.876 | -1.00 | 0.005 | -0.28 | 0.463 | -0.98 | 0.119 | 0.03 | 0.947 |
| Inosine\*Valine | 0.42 | 0.727 | -0.14 | 0.725 | 0.60 | 0.592 | 0.39 | 0.297 | 0.78 | 0.431 | 0.53 | 0.141 | 0.86 | 0.345 | 0.13 | 0.738 | 1.00 | 0.017 | -0.10 | 0.810 | 0.99 | 0.097 | -0.11 | 0.772 |
| Inosine/Valine | 0.81 | 0.394 | 0.41 | 0.272 | 0.92 | 0.259 | 0.40 | 0.286 | 0.99 | 0.098 | 0.12 | 0.755 | 1.00 | 0.012 | -0.12 | 0.755 | 0.85 | 0.351 | 0.02 | 0.982 | 0.93 | 0.236 | 0.12 | 0.755 |
| Inosine+Valine | -0.34 | 0.782 | 0.00 | 1.000 | -0.53 | 0.647 | -0.39 | 0.297 | -0.72 | 0.486 | -0.44 | 0.231 | -0.81 | 0.400 | -0.04 | 0.911 | -1.00 | 0.038 | 0.33 | 0.385 | -0.97 | 0.152 | -0.08 | 0.841 |
| Valine+Inosine+Creatine+Betaine | -0.34 | 0.782 | 0.00 | 1.000 | -0.53 | 0.647 | -0.39 | 0.297 | -0.72 | 0.486 | -0.44 | 0.231 | -0.81 | 0.400 | -0.04 | 0.911 | -1.00 | 0.038 | 0.33 | 0.385 | -0.97 | 0.152 | -0.08 | 0.841 |
| lysoPE(17:0) | 0.58 | 0.606 | 0.41 | 0.272 | 0.74 | 0.471 | 0.02 | 0.965 | 0.88 | 0.310 | -0.24 | 0.527 | 0.94 | 0.224 | 0.10 | 0.789 | 0.98 | 0.138 | 0.20 | 0.613 | 1.00 | 0.024 | 0.61 | 0.082 |
| LysoPE(0:0/22:5) | 0.81 | 0.404 | 0.55 | 0.127 | 0.91 | 0.269 | -0.07 | 0.859 | 0.99 | 0.108 | -0.40 | 0.286 | 1.00 | 0.022 | -0.16 | 0.687 | 0.86 | 0.340 | 0.30 | 0.437 | 0.94 | 0.226 | 0.35 | 0.359 |
| Propionylcarnitine/Butyrylcarnitine | -0.36 | 0.764 | 0.27 | 0.476 | -0.55 | 0.629 | -0.02 | 0.965 | -0.74 | 0.468 | -0.26 | 0.497 | -0.83 | 0.382 | -0.54 | 0.134 | -1.00 | 0.020 | 0.07 | 0.880 | -0.98 | 0.134 | -0.57 | 0.106 |